Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment

US11498968B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Michael CANNARILE · Penzberg, DE
• Anna-Maria Jegg · Penzberg, DE
• Francesca Michielin · Basel, CH
• Carola Ries · Penzberg, DE
• Dominik RUETTINGER · Seehausen, DE
• Martin Weisser · Penzberg, DE

Key dates

• Filing date: Jun 11, 2019
• Grant date: Nov 15, 2022
• Expiry date: Dec 25, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The current invention relates to the combination therapy of an anti-CSF-1R antibody (especially a CSF-1R dimerization inhibitor) in combination with an anti-PD-L1 antibody after PD1/PD-L1 inhibitor treatment failure, corresponding pharmaceutical compositions or medicaments using such combination therapy.